Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Allison

Showing results (601-610 of 647) with videos related to

Pageof 65
Sort By:
Cell Research|January 14, 2015
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25Dalil Hannani, Marie Vétizou, David Enot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2024
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate CancerAna M Aparicio, Rebecca S S Tidwell, Shalini S Yadav, et al.
Nature|July 24, 2024
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapyHussein Sultan, Yoshiko Takeuchi, Jeffrey P Ward, et al.
Nature Medicine|November 28, 2018
Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitisYinghong Wang, Diana H Wiesnoski, Beth A Helmink, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2022
Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and NeckRenata Ferrarotto, Moran Amit, Priyadharsini Nagarajan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2021
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and NeckRenata Ferrarotto, Moran Amit, Priyadharsini Nagarajan, et al.
Nature Medicine|October 13, 2020
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinomaJianjun Gao, Neema Navai, Omar Alhalabi, et al.
Nature|November 28, 2014
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigensMatthew M Gubin, Xiuli Zhang, Heiko Schuster, et al.
Cancer Discovery|December 1, 2020
A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic InterventionSpencer C Wei, Wouter C Meijers, Margaret L Axelrod, et al.
Nature Communications|August 20, 2021
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancerTina Cascone, Annikka Weissferdt, Myrna C B Godoy, et al.
Pageof 65

Showing results (601-610 of 647) with videos related to

Sort By:
Pageof 65
Cell Research|January 14, 2015
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25Dalil Hannani, Marie Vétizou, David Enot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2024
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate CancerAna M Aparicio, Rebecca S S Tidwell, Shalini S Yadav, et al.
Nature|July 24, 2024
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapyHussein Sultan, Yoshiko Takeuchi, Jeffrey P Ward, et al.
Nature Medicine|November 28, 2018
Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitisYinghong Wang, Diana H Wiesnoski, Beth A Helmink, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2022
Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and NeckRenata Ferrarotto, Moran Amit, Priyadharsini Nagarajan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2021
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and NeckRenata Ferrarotto, Moran Amit, Priyadharsini Nagarajan, et al.
Nature Medicine|October 13, 2020
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinomaJianjun Gao, Neema Navai, Omar Alhalabi, et al.
Nature|November 28, 2014
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigensMatthew M Gubin, Xiuli Zhang, Heiko Schuster, et al.
Cancer Discovery|December 1, 2020
A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic InterventionSpencer C Wei, Wouter C Meijers, Margaret L Axelrod, et al.
Nature Communications|August 20, 2021
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancerTina Cascone, Annikka Weissferdt, Myrna C B Godoy, et al.
Pageof 65